Rapid autopsy program for small cell lung cancer patients

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This pilot project aims to establish a rapid autopsy program specifically for patients with small cell lung cancer (SCLC) at the Indiana University Simon Comprehensive Cancer Center. The study involves collaboration among scientists, lung cancer physicians, and pathologists to outline the necessary components for tumor tissue collection. The collected tumor tissues will be utilized for various analyses, including protein and gene analysis, RNA sequencing, and whole exome sequencing, contributing to the identification of biological and molecular markers of SCLC.

Why it matters

Who can join: the full rules

Inclusion Criteria:

1. ≥ 18 years old at the time of informed consent
2. Written informed consent and HIPAA authorization for release of personal health information.
3. Active SCLC diagnosis.

Where it's running

• Indiana University Melvin and Bren Simon Comprehensive Cancer Center
  Indianapolis, Indiana, United States Recruiting
• Roudebush VA Medical Center
  Indianapolis, Indiana, United States Recruiting
• Sidney and Lois Eskenazi Hospital
  Indianapolis, Indiana, United States Recruiting

Study contacts

• Principal investigator: Shadia I. Jalal, MD — Indiana University
• Study coordinator: Gabby Kline, BA
• Email: gabkline@iu.edu
• Phone: (317) 278-2514

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Cirtuvivint plus irinotecan for relapsed small-cell lung cancer

  This trial will test whether adding cirtuvivint to irinotecan helps people with relapsed small-cell lung cancer respond better and live longer.

  Recruiting Phase 1/2 Washington University School of Medicine · St Louis, Missouri · NCT07155200

• Tarlatamab in strong-performance-status small-cell lung cancer

  This trial tests whether tarlatamab can help people with extensive-stage small-cell lung cancer and poor health (ECOG 2) who have already had prior treatment.

  Recruiting at 8 sites Phase 2 AIO-Studien-gGmbH · Berlin and 7 other locations · NCT07803848

• Armored DLL3-SAVVYZ-IL18 CAR T cells for DLL3+ cancers

  Aims to see if DLL3-SAVVYZ-IL18 CAR T cells can be safely given to people with DLL3-positive cancers, including certain small cell lung cancers and other neuroendocrine tumors.

  Recruiting at 7 sites Phase 1 Memorial Sloan Kettering Cancer Center · Basking Ridge, New Jersey and 6 other locations · NCT07783477

• Tarlatamab given under the skin vs by IV in extensive-stage small cell lung cancer after platinum therapy

  This trial tests whether subcutaneous tarlatamab works as well as the IV form for people with extensive-stage small cell lung cancer after platinum chemotherapy.

  Recruiting at 9 sites Phase 3 Amgen · Orlando, Florida and 8 other locations · NCT07778316

• NK Cells Plus Immunotherapy for Extensive-Stage Small Cell Lung Cancer Maintenance

  This study tests whether adding allogeneic NK cell therapy to standard immunotherapy helps people with extensive-stage small cell lung cancer who have disease control after initial chemotherapy and immunotherapy.

  Recruiting Phase 2 Tianjin First Central Hospital · Tianjin, Tianjin Municipality · NCT07759856

• BL-M14D1 plus atezolizumab vs standard therapy in first-line extensive-stage small cell lung cancer

  A first-line treatment for adults with extensive-stage small cell lung cancer tests whether adding BL-M14D1 to atezolizumab and standard chemotherapy helps more than standard care.

  Recruiting at 7 sites Phase 3 SystImmune Inc. · Springdale, Arkansas and 61 other locations · NCT07625644

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.